Patents

European patent allowance granted for enhanced immune response vaccine platform

Published in AIDS Vaccine Week, October 31st, 2005

ImmunoVaccine Technologies Inc. (IVT), a privately held Halifax based life sciences vaccine development company, announced that it has received a patent allowance from the European patent office for their patent application entitled "Vaccines with enhanced immune response and methods for their preparation."

The patent number provided to IVT was 01 983 349.0-2402. All of the claims filed for the patent were allowed following modification of claims 43, 44 and 45, which were modified to conform to European patent presentation.

IVT is best known for its proprietary vaccine enhancement platform, VacciMax. The company has significantly advanced the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Vaccine Week

Source: AIDS Vaccine Week (2005-10-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry